These observations suggest that the efficacy of CXCR4 antagonists in mobilizing neutrophils and correcting peripheral blood neutropenia may be compound-specific and influenced by several factors such as pharmacokinetic properties, tissue distribution, residence time on CXCR4 receptor, and the duration of antagonist treatment. This evidence concerns the gene CXCR4 and neutropenia.